TICKERNERD
Menu
ORGOORGOHealthcare · Drug Manufacturers - Specialty & Generic

ORGO Stock Forecast: Organogenesis Holdings, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$0.82
−8.57% on the day

The 2 Wall Street analysts covering Organogenesis Holdings, Inc. hold a median 12-month price target of $2 — +142.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 27 Oct 2026 — in the upper half.

Market cap
$106.2M
Ticker Nerd rank
50/ 100
Median analyst target
$2.00
Analysts covering
2
Revenue$42.8M−57.5% y/y
Operating income−$52.2M
Net income−$96.3M
Free cash flow−$32.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.8%
1M
−40.2%
YTD
−84.1%
1Y
−80.3%
From 52W high
−87.4%
From 52W low
0.0%
$0.82
$6.54
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ORGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organogenesis Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
50/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Value
88
Size
72
Quality
62
Growth
42
Revisions
39
Issuance
34
Volatility
27
Momentum
3

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ORGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26ORGOHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
0 Buy2 Hold0 Sell
Low $2.00Median $2.00High $2.00

The green dot is the last close — the median target sits +142.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Truist SecuritiesMaintainsHold$3.00 → $2.00
28 May 2026Truist SecuritiesInitiatesHold—
28 May 2026Truist SecuritiesInitiatesHold$3.00
26 Mar 2026BTIGReiteratesBuy—
27 Feb 2026BTIGMaintainsBuy—
26 Dec 2025BTIGReiteratesBuy—
15 Dec 2025BTIGReiteratesBuy—
20 Nov 2025BTIGMaintainsBuy—
26 Sept 2025BTIGReiteratesBuy—
8 Aug 2025Cantor FitzgeraldMaintainsOverweight—
15 July 2025Cantor FitzgeraldReiteratesOverweight—
5 Mar 2025Morgan StanleyMaintainsEqual-Weight—
28 June 2024Lake StreetInitiatesBuy—
1 Mar 2024Cantor FitzgeraldReiteratesOverweight—
7 Feb 2024Cantor FitzgeraldInitiatesOverweight—
27 Dec 2023BTIGMaintainsBuy—
14 Nov 2023Morgan StanleyMaintainsEqual-Weight—
11 Aug 2023Morgan StanleyMaintainsEqual-Weight—
10 Aug 2023BTIGMaintainsBuy—
15 June 2023Morgan StanleyInitiatesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ORGO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ORGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Organogenesis Holdings, Inc. returned −80.3% against +13.6% for the S&P 500, dividends included.

ORGO vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26ORGOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ORGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Organogenesis Holdings, Inc. (ORGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.1×

Cheaper than 42% of US stocks

Price / sales
0.2×

Cheaper than 89% of US stocks

Price / book
0.7×

Cheaper than 76% of US stocks

EV / EBITDA
−27.5×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
−56.7%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.5%

Higher than 9% of US stocks

Gross margin
44.7%

Higher than 55% of US stocks

Operating margin
−119.3%

Higher than 13% of US stocks

Net margin
−18.4%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−25.9%

Higher than 29% of US stocks

Return on assets
−4.1%

Higher than 33% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Organogenesis Holdings, Inc. (ORGO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Organogenesis Holdings, Inc. has a market value of $106.2M and an enterprise value of $266.8M.

  • Revenue in the twelve months to 30 June 2026: $454.6M. The latest quarter shrank 56.7% year on year.

  • Net income over the same four quarters: −$84.2M, a −18.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.86.

  • Free cash flow in the twelve months to 30 June 2026: $20.8M.

  • Shares outstanding: 128.7M.

  • Trailing P/E: 17.1×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Organogenesis Holdings, Inc. employs 854 people — $532K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

ORGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ORGOOrganogenesis Holdings, Inc.$106.2M50
BGMBGM Group Ltd.$119.9M40
DERMJourney Medical Corp.$135.6M63
OGIOrganigram Global, Inc.$136.1M—
CRDLCardiol Therapeutics, Inc.$149.2M—
CPIXCumberland Pharmaceuticals, Inc.$74.2M80
AKBAAkebia Therapeutics, Inc.$176.9M76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Organogenesis Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ORGO news & analysis

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

GlobeNewsWire · 12 Oct 2026positive

Organogenesis announced publication in the Journal of Wound Care of previously released PREPARE trial results evaluating PuraPly®AM plus standard of care against standard of care alone for hard-to-heal diabetic foot ulcers. The trial met its primary endpoint, with statistically significant improvements in wound closure at 12 weeks in the combination group.

Why it matters — The peer-reviewed results provide clinical evidence for PuraPly®AM in the treatment of hard-to-heal diabetic foot ulcers, a difficult-to-treat chronic wound population.

These beaten-down stocks could bounce back in January, if history is any guide

Market Watch · 21 Sept 2026positive

Market Watch reports that tax-loss selling is likely to artificially depress 20 stocks in the fourth quarter, with history suggesting these beaten-down names could bounce back in the new year. ORGO is listed among the stocks expected to experience this pattern.

Why it matters — A ORGO watcher would care because the report suggests the stock may be temporarily depressed by tax-loss selling and could potentially recover in January.

Organogenesis Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026negative

Organogenesis reported a sharp year-over-year decline in second-quarter revenue, driven by ongoing adjustments in the skin substitute market due to Medicare coverage and payment changes. Management noted sequential improvement in product sales and market share gains.

Why it matters — ORGO watchers would care because the revenue decline signals continued headwinds from CMS policy changes, though sequential sales improvement may indicate a potential stabilization.

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Organogenesis Holdings Inc. (ORGO). The transcript covers the company's second-quarter 2026 earnings discussion.

Why it matters — A transcript of the Q2 2026 earnings call provides ORGO watchers with a direct record of management's discussion of the quarter's results and outlook.

FAQ

Frequently asked questions about ORGO stock

What is the ORGO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Organogenesis Holdings, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ORGO stock a buy right now?

Of the 2 analysts covering Organogenesis Holdings, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Organogenesis Holdings, Inc. 50 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ORGO?

As at 27 Oct 2026, Organogenesis Holdings, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will ORGO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +142.5% from the last close, and Ticker Nerd's factor model ranks Organogenesis Holdings, Inc. 50 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ORGO stock forecast for 2030?

No analyst covering Organogenesis Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has ORGO stock performed over the past year?

Organogenesis Holdings, Inc. returned -80.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organogenesis Holdings, Inc. do?

Organogenesis Holdings Inc. Class A Common Stock represents ownership in Organogenesis Holdings Inc., a regenerative medicine company focused on developing, manufacturing, and commercializing products for advanced wound care and surgical and sports medicine.

What is the latest news on ORGO?

The most recent item we track (GlobeNewsWire, 12 Oct 2026): "Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers". Organogenesis announced publication in the Journal of Wound Care of previously released PREPARE trial results evaluating PuraPly®AM plus standard of care against standard of care alone for hard-to-heal diabetic foot ulcers. The trial met its primary endpoint, with statistically significant improvements in wound closure at 12 weeks in the combination group.

Company

About Organogenesis Holdings, Inc.

Organogenesis Holdings Inc. Class A Common Stock represents ownership in Organogenesis Holdings Inc., a regenerative medicine company focused on developing, manufacturing, and commercializing products for advanced wound care and surgical and sports medicine. The company’s portfolio includes bioactive and acellular biomaterials designed to support healing across chronic and acute wound applications, as well as surgical biologics used in orthopedic and spine-related settings. Its products are used by healthcare providers across hospitals, clinics, and other care environments that treat patients with complex wounds and tissue repair needs. Organogenesis Holdings Inc. serves a specialized role in the broader healthcare market by supplying biologic and tissue-based solutions aimed at improving clinical care pathways in wound management and regenerative therapies. The company is headquartered in Canton, Massachusetts.

CEO Mr. Gary S. Gillheeney Sr. · 854 employees · United States · https://organogenesis.com